Erdafitinib

1 Drug classified under this active ingredient

Protein Kinase Inhibitor. Erdafitinib 3,4,5 mg.
F.C. TABS.:56,84. The recom. init. dose of is 8 mg (2tabs ×1/d), with a dose incr. to 9 mg (three 3 mg tabs.) once dly. based on serum phosphate (PO4) levels and tolerabil. at 14 to 21 d. with or without food If vomit. occurs any time after taking Balversa, the next dose should be taken the next day. Tmt. should cont. until dis. progres.or unaccept. toxicity occurs. See lit.
Tmt. of adult pts. with locally advanc. or metastat. urothelial carcinoma (mUC), that has: Suscept. FGFR3 or FGFR2 genet. alterations, and Progres. during or follow. at least one line of prior platinum-contain. chemother., includ. within 12 mnths. of neoadjuvant /adjuvant platinum-contain. chemother.
C/I: Hypersens.